文献速递前列腺癌

转移性激素敏感性前列腺癌临床试验研究是否转化为真实世界患者的治疗可及性?一项系统综述

Does Research from Clinical Trials in Metastatic Hormone-sensitive Prostate Cancer Treatment Translate into Access to Treatments for Patients in the "Real World"? A Systematic Review.
PubMed 文献 · Eur Urol Oncol · 2023-06-27

该系统综述检索MEDLINE和Embase,纳入13篇基于区域或国家数据集的研究(共166876例患者),评估多西他赛或新型激素治疗联合雄激素剥夺治疗在转移性激素敏感性前列腺癌常规实践中的使用率及变异决定因素,发现治疗强化使用率为9.3%至38.1%,年轻、白人、合并症少、居住于更城市化环境的患者更可能接受治疗强化。

要点

  • 多西他赛或新型激素治疗联合ADT在转移性激素敏感性前列腺癌中的使用率为9.3%至38.1%。
  • 年轻、白人、合并症少、居住于更城市化环境的患者更可能接受治疗强化。
  • 在私立学术机构由肿瘤科医生治疗的患者更可能接受多西他赛或新型激素治疗。

核心结论

  • 这些结果强调需要改变真实世界中转移性激素敏感性前列腺癌的治疗方式,利用近期试验中改变实践的结果来优化该患者群体的一线全身治疗。

研究设计与样本

  • 系统综述,检索MEDLINE和Embase,纳入2005年1月后发表的基于区域或国家数据集的转移性激素敏感性前列腺癌治疗使用研究,采用叙述性综合总结结果。
  • 共纳入13篇论文,包括6篇全文和7篇摘要,研究总共包括166876例患者。

主要发现

  • 多西他赛或新型激素治疗(恩扎卢胺、阿帕他胺或阿比特龙)联合ADT的治疗强化使用率在各研究间范围为9.3%至38.1%。
  • 年轻、白人、合并症较少和居住于更城市化环境的患者更可能被处方治疗强化。
  • 在私立学术机构由肿瘤科医生治疗的患者更可能接受多西他赛或新型激素治疗。
  • 社会经济地位不影响接受全身治疗。
  • 新型激素治疗使用率似乎随时间增加。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Since 2015 there have been major advances in the management of primary metastatic hormone-sensitive prostate cancer (mHSPC) following the publication of key clinical trials that demonstrated significant clinical benefits with docetaxel chemotherapy or novel hormone therapy (NHT) in addition to androgen deprivation therapy (ADT). Despite these advances, there is evidence to show that these treatments are not being utilised for mHSPC in clinical practice. OBJECTIVE: To determine the utilisation of docetaxel and NHT in mHSPC in routine practice and the determinants of variation in their use. EVIDENCE ACQUISITION: MEDLINE and Embase were searched systematically for studies on utilisation of treatments for primary mHSPC that were based on regional or national data sets and published after January 2005. Study results were summarised using a narrative synthesis. EVIDENCE SYNTHESIS: Thirteen papers were included in the analysis, six full-text articles and seven abstracts, on studies that included a total of 166 876 patients. The utilisation rate of treatment intensification with either docetaxel or NHT (enzalutamide, apalutamide, or abiraterone) in addition to ADT ranged from 9.3% to 38.1% across the studies. Younger, White patients with fewer comorbidities and living in more urban settings were more likely to be prescribed treatment intensification. Patients treated in private academic institutions by oncologists were more likely to receive docetaxel or NHT. Socioeconomic status did not impact receipt of systemic therapy. NHT utilisation rates appear to have increased over time. CONCLUSIONS: These results highlight the need to change the approach to the treatment of primary mHSPC in the real world by harnessing the practice-changing results from recent trials in this setting to optimise upfront systemic therapy for this patient population. PATIENT SUMMARY: We reviewed the use of treatments for primary metastatic hormone-sensitive prostate cancer that showed a benefit in key clinical trials. We found that these treatments are underused, particularly among certain patient groups.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Dodkins J, Nossiter J, Cook A, et al. Does Research from Clinical Trials in Metastatic Hormone-sensitive Prostate Cancer Treatment Translate into Access to Treatments for Patients in the "Real World"? A Systematic Review. Eur Urol Oncol. 2023. PMID: 37380578. doi:10.1016/j.euo.2023.05.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。